

Cristina Bulai Livideanu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4921522/publications.pdf>

Version: 2024-02-01

48
papers

586
citations

759233

12
h-index

677142

22
g-index

55
all docs

55
docs citations

55
times ranked

777
citing authors

#	ARTICLE	IF	CITATIONS
1	Skin manifestations of hypereosinophilic syndrome are polymorphous and difficult to treat: A retrospective cohort study. <i>Annales De Dermatologie Et De Venereologie</i> , 2022, 149, 139-141.	1.0	2
2	Effectiveness and Safety of Adalimumab, Etanercept and Ustekinumab for Severe Psoriasis in Children Under 12 Years of Age: A French-Italian Daily Practice Cohort (BiPe Jr). <i>Paediatric Drugs</i> , 2022, 24, 281-292.	3.1	6
3	Langerhans cell histiocytosis associated with chronic myelomonocytic leukaemia both harbouring the same BRAF V600E mutation: efficacy of vemurafenib. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e120-e121.	2.4	6
4	VEXAS syndrome in a patient with previous spondyloarthritis with a favourable response to intravenous immunoglobulin and anti-IL17 therapy. <i>Rheumatology</i> , 2021, 60, e314-e315.	1.9	35
5	Neuropsychiatric, cognitive and sexual impairment in mastocytosis patients. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 118.	2.7	3
6	Cutaneous mastocytosis in adults with a serum tryptase level < 20 ng mL ⁻¹ : why we should investigate further. <i>British Journal of Dermatology</i> , 2021, 185, 453-455.	1.5	0
7	Tapinarof-induced folliculitis: The paradigm of activation of the aryl hydrocarbon signaling pathway. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, e37-e38.	1.2	4
8	The association of Greig syndrome and mastocytosis reveals the involvement of the hedgehog pathway in advanced mastocytosis. <i>Blood</i> , 2021, 138, 2396-2407.	1.4	5
9	A nationwide study evaluating the association of autoimmune bullous diseases and acquired haemophilia: description of clinical and prognostic features. <i>British Journal of Dermatology</i> , 2021, , .	1.5	1
10	Efficacy and tolerability of long-pulse Alexandrite laser hair removal for hidradenitis suppurativa. <i>European Journal of Dermatology</i> , 2021, , .	0.6	2
11	Vascular Nd:YAG laser: a therapeutic alternative for large venous lakes of the oral mucosa. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e164-e165.	2.4	1
12	532 nm Q-switched laser for the treatment of hyperpigmentation induced by topical tacrolimus. <i>Journal of Cosmetic and Laser Therapy</i> , 2020, 22, 90-92.	0.9	2
13	Omalizumab in the treatment of adult patients with mastocytosis: A systematic review. <i>Clinical and Experimental Allergy</i> , 2020, 50, 654-661.	2.9	50
14	Mast cell activation syndrome: High frequency of skin manifestations and anaphylactic shock. <i>Allergology International</i> , 2019, 68, 119-121.	3.3	2
15	Omalizumab Therapy for Mast Cell-Mediator Symptoms in Patients with ISM, CM, MMAS, and MCAS. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 2387-2395.e3.	3.8	42
16	Image Gallery: The vulva: an atypical localization of mastocytosis in adulthood. <i>British Journal of Dermatology</i> , 2019, 181, e33.	1.5	1
17	Long-term continuation with secukinumab in psoriasis: association with patient profile and initial psoriasis clearance. <i>Clinical and Experimental Dermatology</i> , 2019, 44, e230-e234.	1.3	12
18	Efficacy of ixekizumab in patients with resistance or incomplete response to secukinumab. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, e338-e341.	2.4	5

#	ARTICLE	IF	CITATIONS
19	Frequency of isolated cutaneous involvement in adult mastocytosis: a cohort study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 1713-1718.	2.4	6
20	Higher prevalence of vertebral fractures in systemic mastocytosis, but not in cutaneous mastocytosis and idiopathic mast cell activation syndrome. <i>Osteoporosis International</i> , 2019, 30, 1235-1241.	3.1	8
21	Focal facial hyperhidrosis associated with internal carotid artery dissection successfully treated with botulinum toxin A. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, e314-e316.	2.4	1
22	Efficacy of ustekinumab in palmoplantar pustulosis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, e204-e206.	2.4	6
23	Changes in interleukin-17A, macrophage-derived chemokine and adiponectin following treatment of psoriasis with calcipotriol plus betamethasone dipropionate aerosol foam: results from the PSO-ABLE study. <i>British Journal of Dermatology</i> , 2018, 178, e33-e34.	1.5	7
24	Trichodysplasia spinulosa associated with HIV infection: clinical response to acitretin and valganciclovir. <i>Clinical and Experimental Dermatology</i> , 2018, 43, 231-233.	1.3	11
25	Extracorporeal Photopheresis: An Efficacious and Well-Tolerated Treatment for Cutaneous and Oral Mucosal Chronic Graft-versus-Host Disease. <i>Dermatology</i> , 2018, 234, 23-30.	2.1	5
26	Hydroxychloroquine as a novel therapeutic approach in mast cell activation diseases. <i>Clinical Immunology</i> , 2018, 194, 75-79.	3.2	10
27	Safety of ultra-rush protocols for hymenoptera venom immunotherapy in systemic mastocytosis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 2260-2263.	5.7	13
28	Prevalence of CD30 immunostaining in neoplastic mast cells. <i>Medicine (United States)</i> , 2018, 97, e10642.	1.0	10
29	Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study. <i>Lancet, The</i> , 2017, 389, 612-620.	13.7	95
30	Systemic treatment of severe adult Atopic dermatitis in clinical practice: analysis of prescribing pattern in a cohort of 241 patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, e423-e424.	2.4	7
31	Azathioprine Hypersensitivity Syndrome: Two Cases of Febrile Neutrophilic Dermatitis Induced by Azathioprine. <i>Case Reports in Dermatology</i> , 2017, 9, 6-11.	0.8	10
32	Prevalence and risk factors for fragility fracture in systemic mastocytosis. <i>Bone</i> , 2017, 105, 219-225.	2.9	28
33	Immunohistochemical staining for diagnosis of cutaneous mastocytosis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, e160-e162.	2.4	5
34	Bone marrow tryptase as a possible diagnostic criterion for adult systemic mastocytosis. <i>Clinical and Experimental Allergy</i> , 2016, 46, 133-141.	2.9	8
35	Photo-induced graft-versus-host disease. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2016, 32, 291-295.	1.5	2
36	Improvement of Microstomia in Scleroderma after Carbon Dioxide Laser Treatment. <i>Case Reports in Dermatology</i> , 2016, 8, 142-150.	0.8	15

#	ARTICLE	IF	CITATIONS
37	Inclusion and exclusion criteria in phase III trials with systemic agents in psoriasis: the external validity of drug development. <i>British Journal of Dermatology</i> , 2016, 175, 636-638.	1.5	26
38	Acquired perforating dermatosis associated with sorafenib therapy. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 328-330.	2.4	7
39	Telangiectasia macularis eruptiva perstans (TMEP): A form of cutaneous mastocytosis with potential systemic involvement. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 885-891.e1.	1.2	30
40	Enzalutamide induced acute generalized exanthematous pustulosis. <i>Journal of Dermatological Case Reports</i> , 2016, 10, 35-38.	1.1	14
41	Angiolymphoid hyperplasia with eosinophilia treated with low-dose methotrexate. <i>JAAD Case Reports</i> , 2015, 1, 342-344.	0.8	5
42	Association of mastocytosis with inflammatory joint diseases: A series of 31 patients. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 44, 362-365.	3.4	12
43	Incidence and risk factors for treatment failure with <i>infliximab</i> in psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, 1323-1324.	2.4	5
44	Joint clinical and pathological review meetings improve patient care: a prospective evaluation in dermatology. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011, 25, 928-932.	2.4	1
45	Purpuric lesions induced by UVA1 spectrum (340-400nm) phototesting in an adult with persistent and severe hydroa vacciniforme. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2010, 26, 104-106.	1.5	2
46	Milia complicating bullous polymorphic light eruption. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2009, 25, 51-52.	1.5	2
47	Cellular phone addiction and allergic contact dermatitis to nickel. <i>Contact Dermatitis</i> , 2007, 57, 130-131.	1.4	34
48	Contact dermatitis to hydrolyzed wheat protein. <i>Contact Dermatitis</i> , 2007, 57, 283-284.	1.4	18